KMKevin S. McFarland

Kevin S. McFarland

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kevin S. McFarland has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Elevated endoplasmic reticulum pH is associated with high growth and bisAb aggregation in CHO cells

    by Kevin S. McFarland, Kaitlin Hegadorn, Michael J. Betenbaugh, Michael W. Handlogten

    Chinese hamster ovary (CHO) bioprocesses, the dominant platform for therapeutic protein production, are increasingly used to produce complex multispecific proteins. Product quantity and quality are affected by intracellular conditions, but these are challenging to measure and often overlooked during process optimization studies. pH is known to impact quality attributes like protein aggregation across upstream and downstream processes, yet the effects of intracellular pH on cell culture performance are largely unknown. Recently, advances in protein biosensors have enabled investigations of intracellular environments with high spatiotemporal resolution. In this study, we integrated a fluorescent pH‐sensitive biosensor into a bispecifc (bisAb)‐producing cell line to investigate changes in endoplasmic reticulum pH (pHER). We then investigated how changes in lactate metabolism impacted pHER, cellular redox, and product quality in fed‐batch and perfusion bioreactors. Our data show pHER rapidly increased during exponential growth to a maximum of pH 7.7, followed by a sharp drop in the stationary phase in all perfusion and fed‐batch conditions. pHER decline in the stationary phase was driven by an apparent loss of cellular pH regulation that occurred despite differences in redox profiles. Finally, we found protein aggregate levels correlated most closely with pHER which provides new insights into product aggregate formation in CHO processes. An improved understanding of the intracellular changes impacting bioprocesses can ultimately help guide media optimizations, improve bioprocess control strategies, or provide new targets for cell engineering.


  • Open Access

    Elevated endoplasmic reticulum pH is associated with high growth and bisAb aggregation in CHO cells

    by Kevin S. McFarland, Kaitlin Hegadorn, Michael Betenbaugh, Michael W. Handlogten

    Chinese hamster ovary (CHO) bioprocesses, the dominant platform for therapeutic protein production, are increasingly used to produce complex multispecific proteins. Product quantity and quality are affected by intracellular conditions, but these are challenging to measure and often overlooked during process optimization studies. pH is known to impact quality attributes like protein aggregation across upstream and downstream processes, yet the effects of intracellular pH on cell culture performance are largely unknown. Recently, advances in protein biosensors have enabled investigations of intracellular environments with high spatiotemporal resolution. In this study, we integrated a fluorescent pH-sensitive biosensor into a bispecifc (bisAb)-producing cell line to investigate changes in endoplasmic reticulum pH (pH ER ). We then investigated how changes in lactate metabolism impacted pH ER , cellular redox, and product quality in fed-batch and perfusion bioreactors. Our data show pH ER rapidly increased during exponential growth to a maximum of pH 7.7, followed by a sharp drop in stationary phase in all perfusion and fed-batch conditions. pH ER decline in stationary phase was driven by an apparent loss of cellular pH regulation that occurred despite differences in redox profiles. Protein aggregate levels correlated positively with pH ER , indicating that aggregation is not solely driven by oxidative stress and cellular protein load. Improved characterization of intracellular changes in bioprocesses can help guide media optimizations, improve bioprocess control strategies or provide new targets for cell engineering.

  • Engineering redox sensors into CHO cells enables near‐real‐time quantification of intracellular redox in bioprocesses

    by Kevin S. McFarland, Jie Zhu, Pritam Sinharoy, Michael J. Betenbaugh, Michael W. Handlogten

    The production of biologics that treat complex diseases, such as cancer, autoimmune, and infectious disease, requires careful monitoring and control of cell cultures. While bioprocess optimizations have dramatically improved production yields, a lack of analytical tools has made it challenging to identify accompanying intracellular improvements. Intracellular redox can diminish the growth and productivity of biologics‐producing cells and adversely impact product quality profiles yet characterizing redox is challenging due to its complex and highly transient nature. In this study, we integrated a fluorescent thiol‐based redox biosensor to monitor intracellular redox in one bisAb‐ and two monoclonal antibody‐producing clonal cell lines in a 14‐day fed‐batch bioreactor. We characterized biosensor functionality using three fluorescence measurement techniques and determined sensor oxidation correlates with the intracellular ratio of reduced (GSH) and oxidized glutathione (GSSG), an important cellular antioxidant. Our fed‐batch bioreactor studies showed that sensor expression minimally affected bioprocess outcomes, including growth, productivity, product quality attributes, or intracellular redox attributes, including mitochondrial reactive oxygen species and total cellular GSH levels in all cell lines tested. Biosensor measurements taken throughout the culture revealed that the intracellular environment in these cell lines became more reduced throughout the culture, with the exception of a high pH condition which became more oxidized. Our results demonstrate the potential of using biosensors to monitor intracellular changes in near‐real‐time with minimal process effects, thus potentially improving future bioprocess optimizations.


  • The interplay of protein engineering and glycoengineering to fine‐tune antibody glycosylation and its impact on effector functions

    by Qiong Wang, Tiexin Wang, Roushu Zhang, Shuang Yang, Kevin S. McFarland, Cheng‐Yu Chung, Hongpeng Jia, Lai‐Xi Wang, John F. Cipollo, Michael J. Betenbaugh

    The N‐glycan pattern of an IgG antibody, attached at a conserved site within the fragment crystallizable (Fc) region, is a critical antibody quality attribute whose structural variability can also impact antibody function. For tailoring the Fc glycoprofile, glycoengineering in cell lines as well as Fc amino acid mutations have been applied. Multiple glycoengineered Chinese hamster ovary cell lines were generated, including defucosylated (FUT8KO), α‐2,6‐sialylated (ST6KI), and defucosylated α‐2,6‐sialylated (FUT8KOST6KI), expressing either a wild‐type anti‐CD20 IgG (WT) or phenylalanine to alanine (F241A) mutant. Matrix‐assisted laser desorption ionization‐time of flight mass spectrometry characterization of antibody N‐glycans revealed that the F241A mutation significantly increased galactosylation and sialylation content and glycan branching. Furthermore, overexpression of recombinant human α‐2,6‐sialyltransferase resulted in a predominance of α‐2,6‐sialylation rather than α‐2,3‐sialylation for both WT and heavily sialylated F241A antibody N‐glycans. Interestingly, knocking out α‐1,6‐fucosyltransferase (FUT8KO), which removed core fucose, lowered the content of N‐glycans with terminal Gal and increased levels of terminal GlcNAc and Man5 groups on WT antibody. Further complement‐dependent cytotoxicity (CDC) analysis revealed that, regardless of the production cells, WT antibody samples have higher cytotoxic CDC activity with more exposed Gal residues compared to their individual F241A mutants. However, the FUT8KO WT antibody, with a large fraction of bi‐GlcNAc structures (G0), displayed the lowest CDC activity of all WT antibody samples. Furthermore, for the F241A mutants, a higher CDC activity was observed for α‐2,6‐ compared to α‐2,3‐sialylation. Antibody‐dependent cellular cytotoxicity (ADCC) analysis revealed that the defucosylated WT and F241A mutants showed enhanced in vitro ADCC performance compared to their fucosylated counterparts, with the defucosylated WT antibodies displaying the highest overall ADCC activity, regardless of sialic acid substitution. Moreover, the FcγRIIIA receptor binding by antibodies did not always correspond directly with ADCC result. This study demonstrates that glycoengineering and protein engineering can both promote and inhibit antibody effector functions and represent practical approaches for varying glycan composition and functionalities during antibody development.


  • Redox as a bioprocess parameter: analytical redox quantification in biological therapeutic production

    by Pritam Sinharoy, Kevin S McFarland, Natalia I Majewska, Michael J Betenbaugh, Michael W Handlogten


  • Process intensification in fed-batch production bioreactors using non-perfusion seed cultures

    by Andrew Yongky, Jianlin Xu, Jun Tian, Christopher Oliveira, Jia Zhao, Kevin McFarland, Michael C. Borys, Zheng Jian Li

    Although process intensification by continuous operation has been successfully applied in the chemical industry, the biopharmaceutical industry primarily uses fed-batch, rather than continuous or perfusion methods, to produce stable monoclonal antibodies (mAbs) from Chinese hamster ovary (CHO) cells. Conventional fed-batch bioreactors may start with an inoculation viable cell density (VCD) of ~0.5 × 106 cells/mL. Increasing the inoculation VCD in the fed-batch production bioreactor (referred to as N stage bioreactor) to 2–10 × 106 cells/mL by introducing perfusion operation or process intensification at the seed step (N-1 step) prior to the production bioreactor has recently been used because it increases manufacturing output by shortening cell culture production duration. In this study, we report that increasing the inoculation VCD significantly improved the final titer in fed-batch production within the same 14-day duration for 3 mAbs produced by 3 CHO GS cell lines. We also report that other non-perfusion methods at the N-1 step using either fed batch or batch mode with enriched culture medium can similarly achieve high N-1 final VCD of 22–34 × 106 cells/mL. These non-perfusion N-1 seeds supported inoculation of subsequent production fed-batch production bioreactors at increased inoculation VCD of 3–6 × 106 cells/mL, where these achieved titer and product quality attributes comparable to those inoculated using the perfusion N-1 seeds demonstrated in both 5-L bioreactors, as well as scaled up to 500-L and 1000-L N-stage bioreactors. To operate the N-1 step using batch mode, enrichment of the basal medium was critical at both the N-1 and subsequent intensified fed-batch production steps. The non-perfusion N-1 methodologies reported here are much simpler alternatives in operation for process development, process characterization, and large-scale commercial manufacturing compared to perfusion N-1 seeds that require perfusion equipment, as well as preparation and storage vessels to accommodate large volumes of perfusion media. Although only 3 stable mAbs produced by CHO cell cultures are used in this study, the basic principles of the non-perfusion N-1 seed strategies for shortening seed train and production culture duration or improving titer should be applicable to other protein production by different mammalian cells and other hosts at any scale biologics facilities.


  • Open Access

    Design and Production of Bispecific Antibodies

    by Qiong Wang, Yiqun Chen, Jaeyoung Park, Xiao Liu, Yifeng Hu, Tiexin Wang, Kevin McFarland, Michael J. Betenbaugh

    With the current biotherapeutic market dominated by antibody molecules, bispecific antibodies represent a key component of the next-generation of antibody therapy. Bispecific antibodies can target two different antigens at the same time, such as simultaneously binding tumor cell receptors and recruiting cytotoxic immune cells. Structural diversity has been fast-growing in the bispecific antibody field, creating a plethora of novel bispecific antibody scaffolds, which provide great functional variety. Two common formats of bispecific antibodies on the market are the single-chain variable fragment (scFv)-based (no Fc fragment) antibody and the full-length IgG-like asymmetric antibody. Unlike the conventional monoclonal antibodies, great production challenges with respect to the quantity, quality, and stability of bispecific antibodies have hampered their wider clinical application and acceptance. In this review, we focus on these two major bispecific types and describe recent advances in the design, production, and quality of these molecules, which will enable this important class of biologics to reach their therapeutic potential.